Most common (≥3% of patients overall) drug-related grade ≥3 AEs, overall and within the dose-escalation and expansion cohorts
| AE (MedDRA preferred term), n (%) . | Dose-escalation cohorts (n = 26) . | Expansion cohorts (n = 40)* . | Total (n = 60) . |
|---|---|---|---|
| Thrombocytopenia | 7 (27) | 18 (45) | 22 (37) |
| Neutropenia | 4 (15) | 7 (18) | 10 (17) |
| Skin and SC tissue disorders† | 1 (4) | 4 (10) | 5 (8) |
| Fatigue | 0 | 4 (10) | 4 (7) |
| Lymphopenia | 0 | 3 (8) | 3 (5) |
| Abdominal pain | 1 (4) | 1 (3) | 2 (3) |
| Hypophosphatemia | 2 (8) | 0 | 2 (3) |
| Leukopenia | 0 | 2 (5) | 2 (3) |
| Orthostatic hypotension | 1 (4) | 1 (3) | 2 (3) |
| WBC count decreased | 1 (4) | 1 (3) | 2 (3) |
| AE (MedDRA preferred term), n (%) . | Dose-escalation cohorts (n = 26) . | Expansion cohorts (n = 40)* . | Total (n = 60) . |
|---|---|---|---|
| Thrombocytopenia | 7 (27) | 18 (45) | 22 (37) |
| Neutropenia | 4 (15) | 7 (18) | 10 (17) |
| Skin and SC tissue disorders† | 1 (4) | 4 (10) | 5 (8) |
| Fatigue | 0 | 4 (10) | 4 (7) |
| Lymphopenia | 0 | 3 (8) | 3 (5) |
| Abdominal pain | 1 (4) | 1 (3) | 2 (3) |
| Hypophosphatemia | 2 (8) | 0 | 2 (3) |
| Leukopenia | 0 | 2 (5) | 2 (3) |
| Orthostatic hypotension | 1 (4) | 1 (3) | 2 (3) |
| WBC count decreased | 1 (4) | 1 (3) | 2 (3) |